MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-10-2022
PLx Pharma ROA Ratio 2011-2025 | PLXP
Annual ROA Ratio PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -60.18 | -57.15 | -110.81 | 4.88 | -53.2 | -124.75 | -57.83 | -49.91 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.88 | -124.75 | -63.62 |
Quarterly ROA Ratio PLx Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -69.92 | -93.49 | -91.48 | -84.2 | -55.98 | -67.73 | -55.91 | -57.59 | -27.16 | -17.95 | 3.0 | -26.48 | -100.0 | -118.62 | -146.46 | -115.54 | -11.15 | -24.32 | -18.86 | -7.02 | -25.87 | -201.45 | -363.86 | -594.25 | -447.76 | -463.25 | -303.15 | -77.45 | -40.85 | -54.97 | -53.61 | -55.58 | -37.88 | -62.47 | -72.94 | -67.54 | -133.19 | -133.19 | -108.6 | -99.59 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.0 | -594.25 | -114.61 |
ROA Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-13.11 | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-115.89 | $ 0.73 | -3.6 % | $ 51.9 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.34 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-65.18 | $ 1.7 | -2.59 % | $ 183 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-71.31 | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-242.23 | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
-3.8 | $ 3.07 | -6.25 % | $ 1.6 B | Canada |
 |
Agile Therapeutics
AGRX
|
-141.05 | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-26.69 | $ 5.11 | -5.46 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
-10.69 | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-34.9 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-8.75 | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-61.13 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
8.78 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-47.69 | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
-41.71 | $ 12.37 | 8.32 % | $ 633 M | USA |
 |
Evoke Pharma
EVOK
|
-110.24 | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
-50.69 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-29.73 | $ 21.43 | 0.3 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
-21.68 | $ 7.18 | 1.99 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
-7.82 | $ 46.29 | -1.64 % | $ 1.51 B | USA |
 |
China Pharma Holdings
CPHI
|
-31.81 | $ 1.53 | -1.92 % | $ 26.7 M |  China |
 |
Bausch Health Companies
BHC
|
-2.16 | $ 6.9 | -0.36 % | $ 2.52 B | Canada |
 |
Organogenesis Holdings
ORGO
|
0.17 | $ 4.78 | -0.83 % | $ 629 M | USA |
 |
Lannett Company
LCI
|
-47.81 | - | 1.15 % | $ 7.11 M | USA |
 |
Pacira BioSciences
PCRX
|
-6.41 | $ 26.61 | 1.22 % | $ 1.23 B | USA |
 |
OrganiGram Holdings
OGI
|
-23.59 | $ 1.8 | -6.19 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-2.52 | $ 3.11 | 22.92 % | $ 43.7 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
6.13 | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
-16.18 | $ 0.88 | -5.3 % | $ 20.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-25.25 | $ 3.55 | -1.11 % | $ 4.41 M | USA |
 |
Solid Biosciences
SLDB
|
-66.1 | $ 5.75 | -2.04 % | $ 235 M | USA |
 |
PetIQ
PETQ
|
0.25 | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-101.27 | $ 4.34 | 6.91 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
-673.3 | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
-1.78 | $ 12.77 | -2.78 % | $ 1.75 B | USA |
 |
ProPhase Labs
PRPH
|
21.06 | $ 0.11 | -0.35 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
-38.66 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-8.65 | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
-16.12 | $ 1.99 | -9.95 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-62.57 | $ 2.4 | -0.83 % | $ 324 M | USA |
 |
OptiNose
OPTN
|
-32.94 | - | - | $ 1.08 B | USA |
 |
cbdMD
YCBD
|
-1.44 | $ 1.19 | -0.83 % | $ 5.13 M | USA |
 |
SCYNEXIS
SCYX
|
52.21 | $ 0.64 | -0.91 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-104.78 | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-33.73 | $ 11.01 | -9.4 % | $ 6.8 B | Canada |
 |
TherapeuticsMD
TXMD
|
-23.73 | $ 1.7 | -2.86 % | $ 17.7 M | USA |
 |
Zomedica Corp.
ZOM
|
-13.64 | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
4.16 | $ 11.68 | 0.29 % | $ 14.2 B | USA |